1092443-98-5

Basic information

• Product Name: benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine
• Synonyms: benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine;N-Benzyl-5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-amine
• CAS NO: 1092443-98-5
• Molecular Formula: C₁₆H₁₇ClN₄
• Molecular Weight: 300.78598
• Mol File: 1092443-98-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine(1092443-98-5)
• EPA Substance Registry System: benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine(1092443-98-5)

Safety Data

• Hazardous Substances Data: 1092443-98-5(Hazardous Substances Data)

Upstream product

• 151521-49-2 4-isopropyl-1H-pyrazol-3-amine 
• 151521-49-2 4-isopropyl-1 H-pyrazol-5-amine 
• 771510-25-9 3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diol 
• 771510-15-7 2-formyl-3-methylbutanenitrile 
• 625-28-5 Isovaleronitrile 
• 100-46-9 benzylamine 
• 771510-32-8 5,7-dichloro-3-iso-propyl-pyrazolo[1,5-a]pyrimidine 

Downstream Products

• 1092444-33-1 benzyl (5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamic acid tert-butyl ester 
• 1256288-44-4 tert-butyl benzyl(5-((6-((tert-butoxycarbonyl)amino)hexyl)amino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-48-8 tert-butyl (R)-benzyl-{5-[1-(tert-butyl-dimethylsilyloxy)-9-(6-fluoropyridin-3-yl)-non-2-ylamino]-3-isopropyl-pyrazolo[1,5-a]pyrimidin-7-yl}carbamate 
• 1092444-49-9 tert-butyl benzyl-((R)-5-(9-(6-fluoropyridin-3-yl)-1-hydroxynonan-2-ylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-62-6 tert-butyl benzyl(3-isopropyl-5-(2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodecan-6-ylamino)pyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-52-4 tert-butyl benzyl(5-(((2S,3R)-1-((tert-butyldimethylsilyl)oxy)-3,4-dihydroxybutan-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-51-3 tert-butyl benzyl(5-(((2S,3S)-1-((tert-butyldimethylsilyl)oxy)-3,4-dihydroxybutan-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-35-3 tert-butyl benzyl(5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)amino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-50-2 (R)-tert-butyl benzyl(5-((1-((tert-butyldimethylsilyl)oxy)but-3-en-2-yl)amino)-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-60-4 tert-butyl benzyl(5-(3-(tert-butyldimethylsilyloxy)propylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-56-8 tert-butyl benzyl(5-(2-(tert-butyldimethylsilyloxy)ethylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-58-0 tert-butyl benzyl(5-((2,2-dimethyl-1,3-dioxolan-4-yl)methylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092443-56-5 BS-195 
• 1092443-55-4 BS-194 

Relevant articles and documents

CDK inhibitor based on organic arsine as well as preparation method and application of CDK inhibitor

The invention provides a CDK inhibitor based on organic arsine as well as a preparation method and application of the CDK inhibitor. Specifically, the invention providese compounds of Formula I, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof; and the invention also discloses a preparation method and application thereof. Definitions of allgroups in the formula are shown in the specification.

Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds

Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-α]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-α]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.

A novel pyrazolo[1,5- a ]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration

Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression. Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs. Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compound, 4k (BS-194), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, respectively). Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases. Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L). Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice. When administered at a concentration of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation. These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.